April 2022

April 15, 2022

April 15, 2022

Categories

From the Co-Chairs

From the Co-Chairs, April 2022

Congress creates a new health care research agency; NCI-MATCH continues to offer treatment options; ECOG-ACRIN plans for first in-person Group Meeting since 2019

April 15, 2022

April 15, 2022

Categories

Active Clinical Trials

Now Enrolling: ECOG-ACRIN Opens a New NCI-MATCH Treatment Arm for dMMR and LAG-3-Positive Cancers as it Continues to Locate Patients with BRAF Mutations

The ground-breaking NCI-MATCH precision medicine cancer trial continues to offer treatment opportunities for adult patients with relapsed, refractory cancers. Lead investigators Nilo Azad, MD, and April Salama, MD, discuss Arms Z1M and H.

April 15, 2022

April 15, 2022

Categories

Special Topics

Enrollment in TMIST Breast Cancer Screening Trial Surpasses Halfway Mark; Recruitment of Women from Diverse Backgrounds is Key to Success

Enrollment doubles in past 17 months due to specific efforts — Black participation rises above 20%

April 15, 2022

April 15, 2022

Categories

Active Clinical Trials

NCI-MATCH: The Blueprint for Future Precision Medicine Trials

In an enormous undertaking, ECOG-ACRIN and the NCI have built the knowledge base and infrastructure for future precision medicine trials. The new Genomics Subcommittee is offering expertise moving forward.

April 15, 2022

April 15, 2022

Categories

Active Clinical Trials

Trial Spotlight: Nadine Tung on the EA1181/CompassHER2 pCR Trial for HER2-Positive Breast Cancer

This study aims to determine if it is safe to omit adjuvant chemotherapy after surgery for patients with pathologic complete response (pCR) after 12 weeks of pre-operative treatment

April 15, 2022

April 15, 2022

Categories

News in Brief

News in Brief, April 2022

Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more